OPR - Delayed Quote • USD ITOS Oct 2024 17.000 call (ITOS241018C00017000) Follow 0.9500 0.0000 (0.00%) At close: February 21 at 9:30 AM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for ITOS241018C00017000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ITOS iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 iTeos to Participate in Upcoming Investor Conferences Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? iTeos Announces 2024 Strategic Priorities and Anticipated Milestones iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect? iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher
